Q2 2025 AngioDynamics Inc Earnings Call Transcript
Key Points
- AngioDynamics Inc (ANGO) reported a strong second quarter with total worldwide revenue of $73 million, representing a 9% year-over-year growth.
- The MedTech segment showed impressive performance, growing 25% year-over-year, driven by growth across all platforms.
- The mechanical thrombectomy business, including Alphavac and Angiovac, grew approximately 46% over the second quarter of last year.
- The company achieved positive adjusted EBITDA of $3.1 million and generated $2.5 million in operating cash flow.
- Significant progress was made with the Nanoknife system, including an expanded FDA indication for prostate tissue ablation and a new CPT code for reimbursement.
- The Med Device segment revenue was flat compared to the prior year, indicating challenges in growth outside the MedTech segment.
- Gross margin decreased by 10 basis points compared to the previous year, primarily due to inflationary pressures and costs associated with the transition to outsourced manufacturing.
- Adjusted EPS was a loss of $0.04 per share, although improved from a loss of $0.08 per share in the previous year.
- The company expects to utilize approximately $10 million of cash in the third quarter before returning to cash generation in the fourth quarter.
- There are ongoing challenges with the transition to outsourced manufacturing, which may create some under absorption in the back half of the fiscal year.
Good morning and welcome to the AngioDynamics fiscal year 2025 second quarter earnings call at this time. (Operator instructions)
The news release detailing AngioDynamics fiscal 2025 second quarter results crossed the wire earlier this morning and is available on the company's website. This conference call is also being broadcast live over the internet at the investors section of the company's website at www.geodynamics.net and the webcast replay of the call will be available at the same site approximately one hour after the end of today's call.
Before we begin, I would like to caution listeners that during the course of this conference call, the company will make projections or forward-looking statements regarding future events including statements about expected revenue adjusted earnings and gross margins for fiscal year 2025. As well as trends that may continue. Management encourages you to review the company's past and future filings with the SEC including without limitation, the company's forms 10-Q and 10-K which
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
